Vzhe-039, a Novel Structurally-Enhanced Allosteric Hemoglobin Effector Inhibits Sickling of SS Erythrocytes In Vitro, and Exhibits Improved Pharmacologic Properties In Vivo
Martin K. Safo(Virginia Commonwealth University), Osheiza Abdulmalik(Children's Hospital of Philadelphia), David Tanya(Virginia Commonwealth University), Qiukan Chen(Children's Hospital of Philadelphia), Mohini S. Ghatge(Children's Hospital of Philadelphia), Yan Zhang(Virginia Commonwealth University), Carla Casu(Children's Hospital of Philadelphia), Guoyan Xu(Children's Hospital of Philadelphia), Jürgen Venitz(National Cancer Institute)
Cited by 2
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
2‐Methoxyestradiol, a Promising Anticancer Agent
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2003|276
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
G Protein–Coupled Receptor Deorphanizations
|The Annual Review of Pharmacology and Toxicology|2011|193